Latest studies
- RecruitingPHASE3
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
This study looks at new ways to treat multiple myeloma. Researchers are testing a drug called elranatamab, alone and with daratumumab, against a standard treatment. The aim is to find better and safer treatments for people who have tried other medicines.
Multiple MyelomaJapan - Active not recruitingPHASE2, PHASE3
A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.
This study looks at a new drug, efgartigimod PH20 SC, for adults with active idiopathic inflammatory myopathy (IIM), a condition causing muscle weakness and inflammation. It compares the drug to a dummy treatment to see if it helps improve muscle strength and overall well-being.
Active Idiopathic Inflammatory MyopathyMyositisDermatomyositisPolymyositisJapan - Active not recruitingPHASE2
Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis
This study is looking into a new medication called NS-229 for Eosinophilic Granulomatosis with Polyangiitis (EGPA), also known as Churg-Strauss Syndrome. We want to see if NS-229 is safe and effective compared to a dummy treatment (placebo) when added to usual care.
Eosinophilic Granulomatosis With PolyangiitisChurg-Strauss SyndromeJapan - Active not recruitingPHASE3
Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD
This study is looking into a new medication called Pelacarsen. It aims to see if this medicine can help people with heart disease who have high levels of a specific type of 'bad' cholesterol (Lipoprotein(a)) reduce their risk of future heart problems.
Cardiovascular Disease and Lipoprotein(a)Japan - Active not recruitingPHASE3
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy
This study looks at a new drug, Sacituzumab Govitecan, for advanced breast cancer. It compares it to standard treatments to see if it can slow cancer growth or spread, helping people live longer and healthier lives.
Locally Advanced or Unresectable Metastatic Breast CancerStage IV Breast CancerJapan - RecruitingPHASE3
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
This study is testing a new medicine, lunsekimig, for adults aged 40-80 with COPD that's not well-controlled. We want to see if it helps improve breathing, is safe, and has manageable side effects compared to a dummy medicine.
Chronic Obstructive Pulmonary DiseaseJapan - RecruitingPHASE3
A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (vWD)
This study looks at a new medicine called Vonicog Alfa for children with severe Von Willebrand Disease (VWD). It checks if this medicine can help prevent bleeding events in children who have previously used other VWD treatments.
Von Willebrand Disease (VWD)Japan - Recruiting
Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body
This study looks at how well a drug called VITRAKVI works and how safe it is for people with TRK fusion cancer. This type of cancer happens when certain genes fuse together. Doctors want to see how VITRAKVI helps patients in real-world use.
Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene FusionJapan - Active not recruitingPHASE3
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC
This study is for men with a certain type of advanced prostate cancer (mCSPC) that has spread and has specific gene changes. It compares a new drug called talazoparib, given with standard treatment enzalutamide, against enzalutamide alone, to see if it's safe and effective.
Prostate CancerJapan - RecruitingPHASE3
An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma
This study looks at a daily tablet called ivosidenib for adults with bile duct cancer that has come back or spread, and has been treated before. It aims to confirm if the treatment is safe and works well, and how it affects quality of life.
CholangiocarcinomaJapan - RecruitingPHASE3
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
This study looks at a new medicine called zilebesiran for people with high blood pressure that isn't well controlled, especially if they also have heart problems or are at high risk of developing them. The aim is to see if zilebesiran can reduce serious heart-related events like heart attacks or strokes.
High Risk Cardiovascular DiseaseHypertensionHigh Cardiovascular RiskJapan - Active not recruitingPHASE2, PHASE3
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
This study investigates an injection called litifilimab for adults with active lupus that mainly affects the skin, known as cutaneous lupus erythematosus (CLE). Researchers want to see if it helps reduce skin symptoms and is safe, especially for those whose current treatments aren't working well.
Subacute Cutaneous Lupus ErythematosusChronic Cutaneous Lupus ErythematosusJapan - Active not recruitingPHASE3
A Study to Evaluate the Safety and Efficacy of Zilganersen (ION373) in Patients With Alexander Disease (AxD)
This study is testing a new medicine, zilganersen, for people with Alexander Disease. It aims to see if the medicine is safe and if it can help improve or steady movement abilities. It's a large study, comparing the medicine to a dummy treatment (placebo).
Alexander DiseaseJapan - RecruitingPHASE2
Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
This study is testing a new medicine called brivekimig for moderate to severe hidradenitis suppurativa (HS). It compares brivekimig to a dummy medicine (placebo) to see if it's safe and helps reduce HS symptoms.
Hidradenitis SuppurativaJapan - RecruitingPHASE3
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
This study is testing a new medicine called iptacopan for people aged 12-60 with a kidney disease called C3 Glomerulopathy (C3G). It aims to see if the medicine is safe and helps improve kidney function compared to a dummy pill.
C3GJapan - Active not recruitingPHASE3
A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)
This study looks at new ways to treat advanced non-small cell lung cancer with a specific genetic change. It aims to see if combining a drug called ramucirumab with existing treatments like erlotinib, gefitinib, or osimertinib can work better than current approaches.
Metastatic Non-Small Cell Lung CancerJapan - Recruiting
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
This study looks at how well Medtronic heart devices, like pacemakers and defibrillators, perform over a long time. It helps ensure these devices are reliable and safe for people with heart conditions such as irregular heartbeats or heart failure.
ArrhythmiaBradycardiaHeart FailureSinus TachycardiaJapan - Recruiting
Exploring the hidden burden of living with Glanzmann thrombasthenia
This study wants to hear from people living with Glanzmann thrombasthenia (GT) and their caregivers. We want to understand the daily challenges and feelings of those affected. Your stories can help improve support and understanding for everyone with GT.
Glanzmann thrombastheniaJapan - Active not recruitingPHASE3
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)
This study investigates a new treatment, CAEL-101, for a serious heart condition called AL amyloidosis. Researchers want to see if CAEL-101 can help patients live longer and reduce hospital stays, alongside their usual medicine, compared to a dummy drug.
AL AmyloidosisJapan - Active not recruitingPHASE3
A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State
This study is looking at a new medicine called Dazodalibep for people with Sjögren's Syndrome. It aims to see how well it helps with symptoms and whether it's safe to use, especially for those with moderate to severe symptoms.
Sjögren's Syndrome (SS)Japan - Active not recruitingPHASE3
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
This study looks at a new combination of drugs, pembrolizumab and enzalutamide, for men with advanced prostate cancer that has spread and no longer responds to hormone therapy. It compares this combination to enzalutamide alone to see if it helps men live longer and stops the cancer from growing.
Prostatic NeoplasmsJapan - RecruitingPHASE1, PHASE2
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
This study is testing a new medicine called linvoseltamab for adults with multiple myeloma that hasn't responded to other treatments. We want to find the safest and most effective dose, understand its side effects, and see if it can help treat the cancer.
Multiple MyelomaJapan - Active not recruitingPHASE3
Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)
This study is testing a new medicine, pembrolizumab, for people in the UK with a type of skin cancer called melanoma that has been removed by surgery but is considered high-risk. It aims to see if the medicine can stop the cancer from coming back.
MelanomaJapan - Active not recruitingPHASE3
A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis
This study is testing new drug combinations, pozelimab and cemdisiran, for adults with a muscle-weakening condition called generalised myasthenia gravis (gMG). It looks at how safe these drugs are and how well they help improve muscle function.
Generalized Myasthenia GravisJapan - Active not recruitingPHASE3
A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations
This study looks at a new drug, erdafitinib, for advanced bladder cancer that has specific genetic changes. Researchers want to see if it works better than standard treatments like chemotherapy or pembrolizumab after previous treatments haven't helped enough.
Urothelial CancerJapan - RecruitingPhase III
A long-term extension (LTE) study of guselkumab in pediatric participants
This study looks at the long-term safety of a medicine called guselkumab for children and young people aged 2-17 with Crohn's disease, ulcerative colitis, or a type of arthritis called juvenile psoriatic arthritis. It's for those who have already benefited from guselkumab in a previous study.
Moderately to severely active ulcerative colitis (UC), moderately to severely active Crohn's disease (CD), Juvenile psoriatic arthritis (jPsA)Japan - RecruitingPHASE3
Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation
This study looks at a new medicine called ravulizumab for adults receiving a kidney transplant from a deceased donor. It aims to see if this medicine can help their new kidney start working well faster, reducing the need for dialysis after the operation.
Delayed Graft FunctionDGFKidney TransplantJapan - RecruitingPHASE3
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
This study looks at a new drug, sevabertinib, for advanced lung cancer with a specific genetic change (HER2 mutation). It compares sevabertinib to standard treatments to see if it works better and is safe.
Advanced Non-small Cell Lung Cancer, HER2 MutationJapan - RecruitingPhase III
Astria STAR-0215-302 trial for Navenibart in Hereditary Angioedema
This study looks at a new medicine called navenibart for hereditary angioedema (HAE). It aims to see how safe it is and how well people tolerate it over a long time. Navenibart might help prevent HAE attacks, which can be severe and painful.
Hereditary angioedemaJapan - RecruitingPHASE3
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
This study compares two treatments for advanced left-sided bowel cancer that hasn't spread. It looks at how long people stay disease-free when given a new drug called amivantamab with chemotherapy, versus a standard drug called cetuximab with chemotherapy.
Colorectal NeoplasmsJapan - RecruitingPHASE3
A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]
This study looks at a new medicine for muscle-weakening conditions called dermatomyositis (DM) and polymyositis (PM). It aims to see how well the medicine, called dazukibart, works to help people with these conditions and if it’s safe.
MyositisJapan - RecruitingPHASE3
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
This study is looking at new drug combinations for people recently diagnosed with a type of blood cancer called multiple myeloma. It compares two new treatments, Teclistamab or Talquetamab, each given with standard drugs, against the usual standard treatment, to see which works best.
Multiple MyelomaJapan - RecruitingPHASE3
A Study to Learn About a Clostridioides Difficile Vaccine in People 65 Years of Age and Older
Researchers are testing a new vaccine for C. difficile, a serious gut infection, in people aged 65 and over. This study aims to see if the vaccine is safe, works well, and helps prevent infections. Participants will get either the vaccine or a dummy shot.
Clostridioides Difficile Associated DiseaseJapan - Active not recruitingPHASE3
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977
This study looks at a medicine called risankizumab for children aged 6 to 17 with moderate to severe psoriasis. It checks for side effects and how well the medicine works in those who were part of an earlier study. Risankizumab is already used for adults with psoriasis.
PsoriasisJapan - RecruitingPHASE3
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
This study is looking at a new drug, Saruparib, for men with high-risk prostate cancer and a faulty BRCA gene. It aims to see if adding Saruparib to standard treatments can help prevent the cancer from spreading.
Prostate CancerJapan - Active not recruitingPHASE3
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
This study is looking at a new medicine called Xaluritamig for men with advanced prostate cancer that has stopped responding to standard hormone therapy. It compares Xaluritamig to existing treatments like Cabazitaxel or other hormone therapies, to see which is more effective at helping men live longer.
Metastatic Castration-resistant Prostate CancerJapan - Enrolling by invitation
Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells
This study is checking on people who've had special cell treatments for cancer in previous Kite studies. We want to see how these treatments affect their health and well-being over a long time, looking at safety and how well they continue to work.
Solid and Hematological MalignanciesJapan - Active not recruitingPHASE3
ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE
This study looks at a new medicine called ravulizumab for people with kidney disease having heart surgery. It aims to see if the medicine can prevent serious kidney problems after the operation. It's for adults aged 18-90.
Chronic Kidney DiseaseCKDCardiac DiseaseCardiopulmonary BypassJapan - Recruiting
The Osteoporotic Fracture Classification-based Scoring System for Treatment Decision in Thoracolumbar Osteoporotic Fractures
This study looks at how a new scoring system helps doctors decide the best treatment for broken bones in the back caused by osteoporosis. It compares how well patients do when doctors follow the score's advice versus when they choose a different path.
Osteoporotic FracturesOsteoporosisJapan - RecruitingPHASE3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
This study looks at the long-term safety and effectiveness of a cancer drug called pembrolizumab (and related treatments) for people with advanced cancers. It's for patients who are already receiving these treatments in other studies and want to continue.
Solid TumorsHematologic MalignanciesJapan - Active not recruitingPHASE3
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
This study looks at new treatments for HER2-positive breast cancer that has spread. It compares an experimental drug, trastuzumab deruxtecan (T-DXd), alone or with another drug, pertuzumab, to standard care, to see if they work better and are safe.
Breast Cancer; HER2-positive; MetastaticJapan - Active not recruitingPHASE3
A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma
This study compares a new cell therapy (Cilta-cel) with standard treatments for multiple myeloma, a type of blood cancer. It's for people whose cancer has returned or isn't responding to their current medicine, especially lenalidomide, to see if the new treatment works better.
Multiple MyelomaJapan - Active not recruitingNA
REDUCE LAP-HF TRIAL II
This study looks at a new tiny device, the IASD System II, for people with heart failure. It aims to see if this implant can improve symptoms and quality of life by helping the heart manage pressure better. Half the people get the implant, and half get a check-up without it.
Heart FailureJapan - Active not recruitingPHASE3
A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP)
This study is looking into a new drug, garetosmab, for adults with Fibrodysplasia Ossificans Progressiva (FOP). We want to find out if it's safe, how well it works, and if it helps with FOP symptoms. It's a Phase 3 trial, meaning it's in the later stages of testing.
Fibrodysplasia Ossificans ProgressivaJapan - Enrolling by invitationPHASE3
Long-Term Extension Study of Vosoritide to Treat Children With Hypochondroplasia
This study looks at the long-term effects and safety of a medicine called vosoritide for children with hypochondroplasia, a condition that affects how bones grow. It's for children who have already been part of an earlier study.
HypochondroplasiaJapan - Active not recruitingPHASE3
Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma
This study looks at a new drug, isatuximab, combined with standard treatments (lenalidomide and dexamethasone) for people with high-risk smoldering multiple myeloma. It aims to see if this combination can prevent the disease from getting worse compared to the standard treatments alone.
Plasma Cell MyelomaJapan - RecruitingPHASE3
Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)
This study compares a new medication, Bomedemstat, with a standard treatment, Hydroxyurea, for people with Essential Thrombocythemia (ET). It wants to see if Bomedemstat works better at controlling ET for those new to treatment.
Essential ThrombocythemiaJapan - Active not recruitingPHASE3
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)
This study is testing a new combination treatment for bladder cancer that hasn't spread. It combines standard chemotherapy and radiotherapy with a new drug called pembrolizumab, which helps your immune system fight cancer. We want to see if this new combination works better.
Urinary Bladder NeoplasmsJapan - Active not recruiting
Observation of Clinical Routine Care for Heart Failure Patients Implanted With BIOTRONIK CRT Devices
This study looks at how well a special device for heart failure, called a CRT, works for people in their everyday lives. It also checks for future heart problems and aims to make the device even better.
Heart FailureJapan - Active not recruitingPHASE3
An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer
This study looks at a new immune-boosting medicine called Nivolumab for people who have had surgery for bladder or kidney drainage system cancer. It compares Nivolumab to a dummy drug to see if it's safe and helps stop the cancer from coming back.
Various Advanced CancerJapan